Orbital Therapeutics
Next-generation multi-modal RNA medicines platform (mRNA, circular, self-amplifying) + delivery
Biotech
📍 Cambridge, MA
Founded 2023
Current Valuation
Private
PRIVATE
Orbital Therapeutics is a Cambridge, MA RNA-medicines company that launched in April 2023 with a $270M Series A — one of the largest ever — led by ARCH Venture Partners with a16z Bio + Health and Newpath Partners. Co-founded and led by CEO Giuseppe Ciaramella (former Moderna/Beam executive), Orbital is building a first-in-kind platform integrating established and emerging RNA modalities (mRNA, circular, self-amplifying) with next-generation delivery.
Company Profile
Growth
Well-funded platform stage after $270M Series A
Last Round
Series A — $270M (Apr 2023) · Lead: ARCH Venture Partners
Fundraising Status
Series A · $270M · 3y 3mo ago
privateTotal raised $270M1 disclosed rounds
Funding History
| Round | Amount | Date | Lead Investor | Post-Money |
|---|
| Series A | $270M | Apr 2023 | ARCH Venture Partners | — |
Founders & Key People
Giuseppe Ciaramella
Investors
ARCH Venture Partners · a16z Bio + Health · Newpath Partners
Products
- Multi-modal RNA platform (mRNA, circular RNA, self-amplifying RNA)
- RNA delivery technologies
Competitors
Sail Biomedicines · Orna Therapeutics · Therna Biosciences
BiotechRNA TherapeuticsmRNATechBio
Private-company numbers are not real-time. Reflects publicly disclosed valuations from press releases, news reports, and tender offers as of recent date. Refreshed quarterly.